
Novartis’ Zolgensma sales fall again as gene therapy market woes persist
Business was booming for Swiss pharma giant Novartis in the second quarter of 2025 with 11% net sales growth riding strong performance from major drugs. But one of the company’s “priority brands” rests squarely at the bottom of the pack, reflecting broader …